Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone vs Sitagliptin in T2DM with Metabolic Syndrome
NCT02480465Phase 4Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lobeglitazone in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02480465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480465.